| Literature DB >> 29527137 |
Jozo Grgic1, Eric T Trexler2,3, Bruno Lazinica4, Zeljko Pedisic1.
Abstract
BACKGROUND: Caffeine is commonly used as an ergogenic aid. Literature about the effects of caffeine ingestion on muscle strength and power is equivocal. The aim of this systematic review and meta-analysis was to summarize results from individual studies on the effects of caffeine intake on muscle strength and power.Entities:
Keywords: Data synthesis; Ergogenic aid; Performance; Power
Mesh:
Substances:
Year: 2018 PMID: 29527137 PMCID: PMC5839013 DOI: 10.1186/s12970-018-0216-0
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Studies included in the analysis: summary of study designs
| Study | Study design | Participants age (years) | Sample size and sex | Resistance/sport training experience | Habitual caffeine intake (mg.d−1)a | Caffeine form | Caffeine dosage (mg.kg−1) | Timing of caffeine ingestion before the experimental session(s) [minutes]) | Exercise(s) used for the muscle strength/power assessment | PEDro score |
|---|---|---|---|---|---|---|---|---|---|---|
| Ali et al. [ | RDB | 24 ± 4 | 10 females | Athletes | 0–300 | Capsule | 6 | 60 | CMJ | 10 |
| Andrade-Souza et al. [ | RDB | 25 ± 3 | 11 males | Athletes | N/A | Capsule | 6 | 60 | CMJ | 8 |
| Arazi et al. [ | RDB | 17 ± 1 | 10 females | Untrained/ Athletes | < 60 | Capsule | 2 and 5 | 60 | LP and ST | 10 |
| Arazi et al. [ | RDB | 21 ± 4 | 15 males | Untrained | N/A | Capsule | 6 | 60 | BP and LP | 10 |
| Astorino et al. [ | RDB | 23 ± 4 | 22 males | Trained | 110 ± 152 | Capsule | 6 | 60 | BP and LP | 10 |
| Bloms et al. [ | RSB | 20 ± 1 | 9 females | Athletes | N/A | Capsule | 5 | 60 | CMJ and SJ | 8 |
| 21 ± 2 | 16 males | |||||||||
| Brooks et al. [ | RDB | 21 ± 3 | 14 males | Untrained | N/A | Capsule | 5 | 60 | MBS | 10 |
| Clarke et al. [ | RDB | 21 ± 2 | 8 males | Athletes | N/A | Capsule | 3 | 60 and during the testing sessions | CMJ | 10 |
| Diaz-Lara et al. [ | RDB | 29 ± 3 | 14 males | Trained/ Athletes | < 60 | Capsule | 3 | 60 | BP and CMJ | 10 |
| Foskett et al. [ | RDB | 24 ± 5 | 12 males | Athletes | 0–350 | Liquid | 6 | 60 | CMJ | 10 |
| Gant et al. [ | RDB | 21 ± 3 | 15 males | Athletes | N/A | Liquid | 260 (fixed) 3.7 on average | 60 and during the testing sessions | CMJ | 10 |
| Gauvin [ | RDB | 22 ± 2 | 23 males | Untrained/ Non-athletes | < 200 per week | Capsule | 7 | 60 | CMJ | 9 |
| Goldstein et al. [ | RDB | 25 ± 7 | 15 females | Trained | < 250 ( | Liquid | 6 | 60 | BP | 10 |
| Grgic et al. [ | RDB | 26 ± 6 | 17 males | Trained/ Non-athletes | 58 ± 92 | Liquid | 6 | 60 | BP, BBS and ST | 9 |
| Martin [ | RDB | 20 ± 1 | 12 males | Trained | N/A | Gel | 75 (fixed) - 0.9 on average | 60 | BP and BBS | 10 |
| Sabblah et al. [ | RSB | 24 ± 3 | 7 females | Trained | N/A | Liquid | 5 | 60 | BP and MBS | 8 |
| 28 ± 6 | 10 males | |||||||||
| Williams et al. [ | RDB | 26 ± 4 | 9 males | Trained | ‘Low’ (no exact values) | Capsule | 300 (fixed) - 3.6 on average | 45 | BP and LPD | 10 |
aintake per day unless stated otherwise; RDB randomized double-blind study, RSB randomized single-blind study, CMJ countermovement jump, SJ squat jump, LP leg press, ST Sargent test, BP bench press, MBS machine-based squat, LPD lat pulldown, BBS barbell back squat
Fig. 1Flow diagram of the search and study selection process
Fig. 2Forest plot showing differences between the effects of placebo and caffeine trials on measures of maximal muscular strength. The size of the plotted squares reflects the relative statistical weight of each study. The numbers on the x-axis denote the standardized mean differences expressed as Hedge’s g. The horizontal lines denote the respective 95% confidence intervals (CI)
Fig. 3Forest plot showing differences between the effects of placebo and caffeine trials on measures of upper-body maximal muscle strength. The size of the plotted squares reflects the relative statistical weight of each study. The numbers on the x-axis denote the standardized mean differences expressed as Hedge’s g. The horizontal lines denote the respective 95% confidence intervals (CI)
Fig. 4Forest plot showing differences between the effects of placebo and caffeine trials on measures of lower-body maximal muscle strength. The size of the plotted squares reflects the relative statistical weight of each study. The numbers on the x-axis denote the standardized mean differences expressed as Hedge’s g. The horizontal lines denote the respective 95% confidence intervals (CI)
Results from the subgroup meta-analyses
| Subgroup analysis | SMD [95% CI] | Mean caffeine dose (mg.kg−1[range]) | |
|---|---|---|---|
| Strength outcomes | |||
| Upper body strength | 0.21 [0.02, 0.39] | 0.026 | 4.7 [0.9–6] |
| Lower body strength | 0.15 [−0.05, 0.34] | 0.147 | 4.8 [0.9–6] |
| Capsule form of caffeine | 0.27 [0.04, 0.50] | 0.023 | 4.7 [2–6] |
| Liquid form of caffeine | 0.11 [−0.17, 0.39] | 0.462 | 6 [6] |
| Males | 0.21 [0.02, 0.41] | 0.034 | 4.7 [0.9–6] |
| Females | 0.15 [−0.13, 0.43] | 0.294 | 5 [2–6] |
| Trained participants | 0.18 [−0.02, 0.37] | 0.076 | 4.8 [0.9–6] |
| Untrained participants | 0.27 [−0.09, 0.63] | 0.144 | 4.8 [2–5] |
| Power outcomes | |||
| Capsule form of caffeine | 0.14 [−0.06, 0.34] | 0.174 | 4.6 [2–7] |
| Liquid form of caffeine | 0.24 [−0.06, 0.54] | 0.124 | 5.2 [3.7–6] |
| Males | 0.16 [−0.02, 0,34] | 0.081 | 5.3 [3–7] |
| Females | 0.23 [−0.23, 0.69] | 0.323 | 4.8 [2–6] |
| Athletes | 0.23 [0.03, 0.42] | 0.025 | 4.4 [2–6] |
| Non athletes | 0.03 [−0.33, 0.40] | 0.854 | 6.5 [6–7] |
| Countermovement jump | 0.14 [−0.04, 0.32] | 0.138 | 5.0 [3.7–7] |
| Sargent test | 0.31 [−0.09, 0.70] | 0.129 | 4.3 [2–6] |
SMD standardized mean difference, CI confidence interval
Fig. 5Forest plot showing differences between the effects of placebo and caffeine trials on measures of muscle power expressed as vertical jump height. The size of the plotted squares reflects the relative statistical weight of each study. The numbers on the x-axis denote the standardized mean differences expressed as Hedge’s g. The horizontal lines denote the respective 95% confidence intervals (CI)